#None #Menarini Group #Bofanglutide #Gan & Lee

Gan & Lee and Menarini Group Join Forces for Bofanglutide Development in Europe

In a significant move for the pharmaceutical industry, Gan & Lee Pharmaceuticals, a prominent player in the Chinese biotech scene, has formed an exclusive partnership with Italian multinational firm Menarini Group. This cooperation specifically aims to facilitate the development and commercial launch of Bofanglutide (GZR18), an innovative treatment designed for adults affected by obesity or those who are overweight.

An Overview of Bofanglutide

Bofanglutide, classified as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is currently under clinical investigation. With a unique bi-weekly subcutaneous administration schedule, it potentially reduces medication frequency by 50% compared to weekly GLP-1 medications. Initial results from pivotal Phase 3 trials in China, alongside Phase 2 studies conducted in the U.S., point toward promising efficacy in weight loss and a tolerability profile similar to other drugs in the same class.

Terms of the Agreement

Under this license agreement, Gan & Lee will be entitled to an upfront payment of €62 million, in addition to milestone payments that can accumulate to €664 million. Moreover, Gan & Lee will earn royalties based on the net sales within the licensed regions, though the total potential transaction value (excluding royalties) could reach up to €726 million. Menarini assumes responsibility for regulatory submissions and market commercialization across a diverse geography covering 39 countries, including all 27 EU member states, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and several Balkan nations.

This strategic partnership not only marks a significant step for Menarini in enhancing their footprint in metabolic health — a crucial area amidst a rising patient demographic — but also strengthens Gan & Lee’s pursuit of global expansion, leveraging innovative product development.

Statements from Leadership

Dr. Wei Chen, CEO of Gan & Lee, expressed enthusiasm regarding the collaboration, stating, "This alliance paves a crucial pathway for Bofanglutide's entry into the European market and represents a landmark moment in transforming Gan & Lee from an insulin leader into a global innovator in metabolic diseases." Meanwhile, Elcin Barker Ergun, CEO of Menarini Group, acknowledged the clinical trial outcomes thus far, emphasizing the drug’s differential bi-weekly dosing and the significance of this partnership in bringing an important therapeutic option to patients across their operational territories.

Future Directions

Moving forward, Gan & Lee is diligently pushing its global development plan for Bofanglutide and plans to initiate a comprehensive Phase 3 clinical program to support regulatory approval in both Europe and other highly regulated markets. The company aims to progressively enhance its global presence through pioneering research and the introduction of high-quality products.

Gan & Lee's Vision

Bofanglutide stands as a cornerstone within Gan & Lee’s innovative product lineup as it seeks to solidify its reputation in managing diabetes and obesity while continuing to push the boundaries in chemical and biological drug development. With a strategic focus on several therapeutic areas, Gan & Lee remains committed to advancing health outcomes for patients worldwide.

Menarini Group's Commitment

Menarini Group, based in Florence and active in 140 countries, recorded a robust turnover of €4.88 billion. The group focuses on key therapeutic areas, including cardiometabolic health, oncology, gastroenterology, and pain management. Their dedication to high standards in innovation and production remains a testament to their ongoing contribution to global health.

Amidst the growing prevalence of obesity and related metabolic disorders, the collaboration between Gan & Lee and Menarini highlights a promising future in advancing treatment options and enhancing patient care across Europe and beyond.